EverPoint Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

EverPoint Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8.37M	Buy	525,000 +75,000	+17%	+$1.21M	0.16%	164
2016 Q3	$7.49M	Buy	+450,000	New	+$6.06M	0.13%	190
2015 Q4	–	Sell	-1,000,000	Closed	-$11.3M	–	536
2015 Q3	$11.3M	Buy	1,000,000 +100,000	+11%	+$1.22M	0.29%	94
2015 Q2	$11.4M	Buy	+900,000	New	+$9.71M	0.21%	149

Other funds holding VNDA

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EverPoint Asset Management's VNDA Position: Q4 2016 in Review

EverPoint Asset Management increased its Vanda Pharmaceuticals (VNDA) stake by 17% in Q4 2016, buying an estimated $1.21M and bringing the position to 525,000 shares worth $8.37M. The position accounts for 0.16% of the portfolio, ranked #164.

EverPoint Asset Management first reported a position in VNDA in Q2 2015 and has held it in 4 quarters since. The position peaked at $11.4M in Q2 2015. 141 funds tracked by Wall St. Rank hold VNDA as of Q4 2016.

EverPoint Asset Management held 525,000 shares of Vanda Pharmaceuticals worth $8.37M as of Q4 2016.
EverPoint Asset Management bought 75,000 Vanda Pharmaceuticals shares in Q4 2016, an estimated $1.21M.
Vanda Pharmaceuticals made up 0.16% of EverPoint Asset Management's portfolio in Q4 2016, its #164 holding.
EverPoint Asset Management first reported a position in Vanda Pharmaceuticals in Q2 2015 and has held it in 4 quarters since.
EverPoint Asset Management's Vanda Pharmaceuticals position peaked at $11.4M in Q2 2015.
141 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.